Answers are grounded in this paper and cite their sources.
A polyvalent antibody-binding lumazine synthase protein cage nanoparticle (ABD–AaLS) is constructed by genetically fusing lumazine synthase and antibody-binding domains. ABD–AaLS effectively displays targeting antibodies in an orientation-controlled manner.
No takes yet. Share an insight, caveat, or question.
Kim et al. (2016) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: